SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-084969
Filing Date
2023-11-09
Accepted
2023-11-09 09:15:30
Documents
13
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea187953-8k_cadrenal.htm   iXBRL 8-K 26361
2 PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON NOVEMBER 9, 2023 ea187953ex99-1_cadrenal.htm EX-99.1 14644
  Complete submission text file 0001213900-23-084969.txt   220355

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20231109.xsd EX-101.SCH 3015
4 XBRL LABEL FILE cvkd-20231109_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cvkd-20231109_pre.xml EX-101.PRE 22359
7 EXTRACTED XBRL INSTANCE DOCUMENT ea187953-8k_cadrenal_htm.xml XML 3417
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 231390330
SIC: 2834 Pharmaceutical Preparations